NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.00 +0.61 (+11.32 %)
(As of 04/26/2019 07:36 AM ET)
Previous Close$5.39
Today's Range$5.32 - $6.09
52-Week Range$1.85 - $6.09
Volume6.10 million shs
Average Volume1.58 million shs
Market Capitalization$616.82 million
P/E RatioN/A
Dividend YieldN/A
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CPRX



Sales & Book Value

Annual Sales$500,000.00
Book Value$0.49 per share


Net Income$-34,000,000.00


Market Cap$616.82 million
Next Earnings Date5/8/2019 (Estimated)

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its quarterly earnings data on Monday, March, 18th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The biopharmaceutical company earned $0.50 million during the quarter. View Catalyst Pharmaceuticals' Earnings History.

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Catalyst Pharmaceuticals.

What price target have analysts set for CPRX?

4 analysts have issued 12 month price objectives for Catalyst Pharmaceuticals' stock. Their predictions range from $6.00 to $10.00. On average, they expect Catalyst Pharmaceuticals' share price to reach $7.3750 in the next year. This suggests a possible upside of 22.9% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals.

What is the consensus analysts' recommendation for Catalyst Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals.

What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?

Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and increase our PT to $10 from $9 on CPRX following the company’s 4Q18 earnings call this AM. Despite just 2 months into the launch, we are impressed by the initial metrics reported today for Firdapse, with faster than expected transitioning of patients on 3,4-DAP to commercial drug, favorable insurance timelines and a growing number of new patients that were not previously on 3,4-DAP. The company reported net loss of $0.14 for the quarter and $0.33 for the year, and ended 2018 with $58.5M in cash." (3/19/2019)
  • 2. According to Zacks Investment Research, "Catalyst is developing Firdapse, which is the only candidate in late-stage development, for additional indications. All the other candidates are in early stages of development. Thus, the successful development and commercialization of drug candidates is highly crucial for the company. The company’s share price movement shows that the stock has underperformed the industry year to date. Loss estimates have widened ahead of the Q4 earnings release. The company has an average positive earnings surprise history. However, In November 2018, Firdapse was approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. Firdapse is the first approved product for Catalyst and thus is a big boost for the company. With the approval, the company will start generating revenues.  Firdapse becomes the first FDA approved treatment for LEMS." (2/13/2019)
  • 3. HC Wainwright analysts commented, "We raised our PT to $9 from $6 in view of the additional color on the commercial front. We adjusted the launch cost of and lowered the peak penetration from 25% to 18%." (12/14/2018)

Has Catalyst Pharmaceuticals been receiving favorable news coverage?

Media coverage about CPRX stock has been trending negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 6,650,921 shares, a decrease of 22.8% from the March 15th total of 8,620,737 shares. Based on an average trading volume of 4,573,944 shares, the days-to-cover ratio is presently 1.5 days. Currently, 7.0% of the company's shares are sold short. View Catalyst Pharmaceuticals' Current Options Chain.

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), SLS International (SLS), Synergy Pharmaceuticals (SGYP), Cognex (CGNX), Verastem (VSTM), Inovio Pharmaceuticals (INO), Exelixis (EXEL), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE) and Trevena (TRVN).

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the folowing people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
  • Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
  • Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63)

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.11%), FNY Investment Advisers LLC (0.02%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.

Which institutional investors are buying Catalyst Pharmaceuticals stock?

CPRX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, BNP Paribas Arbitrage SA and Virtu Financial LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $6.00.

How big of a company is Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals has a market capitalization of $616.82 million and generates $500,000.00 in revenue each year. The biopharmaceutical company earns $-34,000,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]

MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/26/2019 by Staff

Featured Article: Fiduciary

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel